학술논문
3回の同種造血幹細胞移植後の末期腎不全に対し生体腎移植を施行したPhiladelphia染色体陽性急性リンパ芽球性白血病 / Kidney transplantation for end-stage renal disease after third allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
Document Type
Journal Article
Author
Aiko IGARASHI; Akihiko NISHIJIMA; Akihito OHTA; Atsushi HAMAMURA; Gaku OSHIKAWA; Hiroaki SHIMIZU; Kazuteru OHASHI; Kazuya OMOTO; Kiyoko SUDA; Kosuke YOSHIOKA; Kyoko HARAGUCHI; Naoki SHINGAI; Noriko DOKI; Shinya ISHIDA; Shuhei KUROSAWA; Takashi TOYA; Takeshi KOBAYASHI; Yasushi SENOO; Yoshiki OKUYAMA; Yuho NAJIMA; Yutaro HINO; 五十嵐 愛子; 原口 京子; 吉岡 康介; 名島 悠峰; 土岐 典子; 大橋 一輝; 太田 哲人; 奥山 美樹; 妹尾 寧; 小林 武; 尾本 和也; 押川 学; 新谷 直樹; 日野 裕太郎; 清水 啓明; 濵村 貴史; 石田 信也; 西島 暁彦; 遠矢 嵩; 須田 潔子; 黒澤 修兵
Source
臨床血液 / Rinsho Ketsueki. 2024, 65(1):7
Subject
Language
Japanese
ISSN
0485-1439
1882-0824
1882-0824
Abstract
An 18-year-old man underwent allogenic bone marrow transplantation (BMT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ph+ALL relapsed 3 months after the first BMT, and the patient underwent a second BMT. However, Ph+ALL relapsed 4 months after the second BMT, and he received a haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) from his father. Molecular complete remission was confirmed 29 days after haplo-PBSCT. However, the patient needed dialysis for end-stage renal disease due to thrombotic microangiopathy 3 years and 2 months after haplo-PBSCT. He received a kidney transplantation from his father 7 years and 10 months after haplo-PBSCT, and got off dialysis after the kidney transplantation. Immunosuppressive therapy with methylprednisolone, tacrolimus, and mycophenolate mofetil was started for kidney transplantation, but the dose of immunosuppressive agents was reduced successfully without rejection soon after kidney transplantation. The patient has maintained long-term remission since the haplo-PBSCT, and his kidney function was restored by the kidney transplantation from his father.